Jeff Stewart

“Dude, just to reiterate what Rupal said, I mean, the profile's very, very nice. And certainly the way we look at it, we'll have RINVOC in AD through 2037. And so when you look at our ability to co-position assets, we've been very successful at that, whether it's been PSA or IDD.”

“No, we don't believe that we would have to wait until we complete the full construction of, let's say, similar to the DUPI label. We think that we're going to have quite a differentiated product here.”

“I'll start with the quarterly results for immunology, which delivered total revenues of $7.3 billion, reflecting impressive sales growth of $1 billion. SkyRizzy total sales were $4.5 billion, up 29.2% on an operational basis, exceeding our expectations.”

“I'll start with the quarterly results for immunology, which delivered total revenues of approximately $8.6 billion. Skyrisi total sales were $5 billion, reflecting operational growth of 31.9%.”

“Looking at our quarterly results, we continue to demonstrate excellent commercial execution across our therapeutic portfolio. I’ll start with immunology, which delivered global revenues of more than $6.7 billion, reflecting growth of 13.3% on an operational basis.”